My guess is that Organova is using it as some sort of publicity stunt. Thing is, aren't they a publicly traded company? Would that be considered stock manipulation of some sorts, if they know they really won't have a liver printed this year?

I'm surprised that the Regenovo 3D-Bioprinter showed up at CES.